75,481 Shares in Henry Schein, Inc. $HSIC Purchased by Foyston Gordon & Payne Inc

Key Points

• Foyston Gordon & Payne Inc. purchased 75,481 Henry Schein shares worth approximately $6.3 million, establishing a 0.07% stake. Institutional investors and hedge funds collectively own 96.62% of the company.
• Analysts maintain a “Moderate Buy” consensus rating, with an average price target of $92.93; current targets range from $82 to $100.
• Henry Schein reported quarterly EPS of $1.27, exceeding estimates of $1.24, while revenue rose 6.7% year over year to $3.46 billion. The stock opened at $88.50, near its 52-week high of $92.18.

Foyston Gordon & Payne Inc purchased a new position in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 75,481 shares of the company's stock, valued at approximately $6,304,000. Foyston Gordon & Payne Inc owned 0.07% of Henry Schein as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in HSIC. CYBER HORNET ETFs LLC acquired a new position in shares of Henry Schein in the 2nd quarter worth approximately $25,000. MUFG Securities EMEA plc acquired a new stake in Henry Schein in the 2nd quarter valued at $27,000. Federated Hermes Inc. acquired a new stake in Henry Schein in the 4th quarter valued at $32,000. Los Angeles Capital Management LLC bought a new stake in Henry Schein in the fourth quarter valued at $37,000. Finally, Trust Co. of Vermont bought a new stake in Henry Schein in the second quarter valued at $42,000. 96.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on HSIC shares. BMO Capital Markets started coverage on Henry Schein in a report on Wednesday, July 8th. They set a "market perform" rating and a $85.00 price objective for the company. UBS Group set a $94.00 target price on shares of Henry Schein and gave the stock a "neutral" rating in a research report on Wednesday, August 5th. Stifel Nicolaus set a $95.00 price target on shares of Henry Schein in a report on Wednesday, August 5th. Barclays restated an "overweight" rating and issued a $100.00 price target (up from $86.00) on shares of Henry Schein in a research report on Thursday, August 6th. Finally, Mizuho dropped their price objective on shares of Henry Schein from $88.00 to $82.00 and set a "neutral" rating for the company in a report on Wednesday, May 6th. Nine research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Henry Schein has an average rating of "Moderate Buy" and an average price target of $92.93.

Henry Schein Stock Up 0.0%

NASDAQ:HSIC opened at $88.50 on Friday. Henry Schein, Inc. has a 1 year low of $61.94 and a 1 year high of $92.18. The stock has a 50-day moving average price of $85.74 and a two-hundred day moving average price of $79.52. The stock has a market cap of $9.86 billion, a price-to-earnings ratio of 25.80, a PEG ratio of 1.69 and a beta of 0.80. The company has a current ratio of 1.32, a quick ratio of 0.73 and a debt-to-equity ratio of 0.60.

Henry Schein (NASDAQ:HSIC - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.03. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%.The business had revenue of $3.46 billion for the quarter, compared to analysts' expectations of $3.37 billion. During the same quarter in the previous year, the business posted $1.10 EPS. Henry Schein's revenue for the quarter was up 6.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. As a group, equities analysts expect that Henry Schein, Inc. will post 5.35 earnings per share for the current year.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source